ULTOMIRIS (Alexion Pharmaceuticals Australasia Pty Ltd)
Product name
ULTOMIRIS
Date registered
Evaluation commenced
Decision date
Approval time
90 (120 working days)
Active ingredients
ravulizumab
Registration type
EOI
Indication
ULTOMIRIS is approved for the new indication as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.